Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer.
暂无分享,去创建一个
V. Beneš | C. von Kalle | R. Eils | T. Rausch | J. Korbel | A. Stütz | C. Plass | H. Lehrach | B. Hutter | N. Jäger | G. Sauter | M. Sultan | M. Yaspo | B. Brors | M. Fälth | T. Schlomm | H. Sültmann | Rolf Kabbe | D. Parkhomchuk | V. Amstislavskiy | Benjamin Raeder | T. Zichner | S. Steurer | R. Simon | S. Minner | M. Graefen | H. Huland | M. Kluth | J. Weischenfeldt | C. Lawerenz | S. Radomski | R. Claus | Lei Gu | H. Stehr | H. Warnatz | H. Sirma | J. Eils | R. Kuner | D. Weichenhan | Manfred Schmidt | S. Gade | L. Feuerbach | K. Schlangen | D. Wuttig | O. Bogatyrova | C. Gerhäuser | Po-Hsien Huang | C. Bartholomae | Nina Amschler | T. Haß | Rami Galal | Jovisa Gjoni | C. Baer | Sawinee Masser | M. Mader | M. Avci | L. Burkhardt | A. Krohn | Laura Stumm | K. Grupp | Malte Mader | Henning Stehr | Maria Fälth | M. Schmidt | B. Raeder
[1] P. Carroll,et al. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation , 2007, Cancer.
[2] S. Varambally,et al. Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer , 2009, Science.
[3] C. Cooper,et al. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer , 2012, Modern Pathology.
[4] M. DePristo,et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.
[5] D. Dearnaley,et al. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival , 2006, British Journal of Cancer.
[6] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[7] Thomas Zichner,et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis , 2012, Bioinform..
[8] H. Schlüter,et al. ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.
[9] H. Moch,et al. Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY , 1996, The Journal of pathology.
[10] Martin J. Aryee,et al. Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements , 2010, Nature Genetics.
[11] Chawnshang Chang,et al. Endocrine mechanisms of disease: Expression and degradation of androgen receptor: mechanism and clinical implication. , 2003, The Journal of clinical endocrinology and metabolism.
[12] S. Nelson,et al. BFAST: An Alignment Tool for Large Scale Genome Resequencing , 2009, PloS one.
[13] Sebastian D. Mackowiak,et al. miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades , 2011, Nucleic acids research.
[14] Jie Zhang,et al. Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in Cancer , 2009, Cell.
[15] A. Sivachenko,et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.
[16] A. Knudson. Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.
[17] Jianfeng Xu,et al. Deletion of a Small Consensus Region at 6q15, Including the MAP3K7 Gene, Is Significantly Associated with High-Grade Prostate Cancers , 2007, Clinical Cancer Research.
[18] H. Lähdesmäki,et al. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer , 2012, Oncogene.
[19] David T. W. Jones,et al. Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations , 2012, Cell.
[20] Jin Woo Kim,et al. DNA copy number alterations in prostate cancers: A combined analysis of published CGH studies , 2007, The Prostate.
[21] D. Berney,et al. Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. , 2010, Cancer research.
[22] Guidelines Eau. EUROPEAN ASSOCIATION OF UROLOGY , 2003 .
[23] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.
[24] Andrew J Vickers,et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[26] J. Brooks,et al. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness , 2012, Oncogene.
[27] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[28] Stephen J. Salipante,et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers , 2011, Proceedings of the National Academy of Sciences.
[29] Antony V. Cox,et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing , 2008, Nature Genetics.
[30] D. Lin,et al. Treatment and survival outcomes in young men diagnosed with prostate cancer , 2009, Cancer.
[31] Beatrice S Knudsen,et al. Mechanisms of prostate cancer initiation and progression. , 2010, Advances in cancer research.
[32] Michael C. Rusch,et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution , 2011, Nature Methods.
[33] C. Plass,et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.
[34] M. Stratton,et al. The cancer genome , 2009, Nature.
[35] T. Borodina,et al. Transcriptome analysis by strand-specific sequencing of complementary DNA , 2009, Nucleic acids research.
[36] A. Chokkalingam,et al. Prostate cancer epidemiology. , 2006, Frontiers in bioscience : a journal and virtual library.
[37] Tim Beißbarth,et al. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling , 2011, BMC Cancer.
[38] Arul M Chinnaiyan,et al. Common gene rearrangements in prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] James A Hanley,et al. 20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.
[40] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[41] J. Eisman,et al. Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. , 2007, The Journal of clinical endocrinology and metabolism.
[42] S. Terry,et al. Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells , 2006, Oncogene.
[43] J. Mckinlay,et al. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study , 2005, Clinical endocrinology.
[44] Marcel H. Schulz,et al. A Global View of Gene Activity and Alternative Splicing by Deep Sequencing of the Human Transcriptome , 2008, Science.
[45] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[46] Michael Rehli,et al. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. , 2006, Cancer research.
[47] S. Balk,et al. The Androgen Receptor Recruits Nuclear Receptor CoRepressor (N-CoR) in the Presence of Mifepristone via Its N and C Termini Revealing a Novel Molecular Mechanism for Androgen Receptor Antagonists* , 2005, Journal of Biological Chemistry.
[48] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[49] Mark D. Johnson,et al. Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion , 2011, Proceedings of the National Academy of Sciences.
[50] S. Dhanasekaran,et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.
[51] Amy E. Hawkins,et al. DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.
[52] Zhaohui S. Qin,et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.
[53] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[54] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[55] A. Haese*,et al. Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.
[56] Chawnshang Chang,et al. Expression and Degradation of Androgen Receptor: Mechanism and Clinical Implication , 2003 .
[57] Thomas Wiegel,et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.
[58] Michael Moser,et al. Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression. , 2012, Biochemical and biophysical research communications.